Depression and anxiety in pregnancy during COVID-19: A rapid review and meta-analysis

•This rapid review and meta-analysis assessed the prevalence of depression and anxiety in pregnancy during the COVID-19 pandemic (N = 47,677 and 42,773 respectively).•Worldwide estimates suggest that over one in four pregnant women are experiencing clinically elevated symptoms of depression (25.6%); rates are higher for clinically significant anxiety (30.5%).•The prevalence of anxiety in pregnancy was higher later in the pandemic.•Routine screening and treatment for depression and anxiety during pregnancy should be prioritized. The study rapidly reviewed and meta-analyzed the worldwide prevalence of depression and anxiety among pregnant women during the COVID-19 pandemic. A systematic search of the literature and meta-analyses were conducted from December 2019 – February 2021 with a total of 46 studies meeting inclusion criteria. Depression was assessed in 37 studies (N = 47,677), with a pooled prevalence of 25.6%. Anxiety was assessed in 34 studies (N = 42,773), with a pooled prevalence of 30.5%; moderation by time showed that prevalence of anxiety was higher in studies conducted later in the pandemic.